Caryn Peterson
Vermögen: 42 790 $ am 30.06.2026
Vermögen: 42 790 $ am 30.06.2026
Caryn L.
Peterson was the founder of DSC Associates LLC, founded in 2004, and served as Managing Partner from 2004 to 2018.
Ms. Peterson is currently Chief Executive Officer at Alevium Pharmaceuticals, Inc. since 2009, Director at Aspen Neuroscience, Inc. since 2021, and Chief Development Officer at Gossamer Bio, Inc. since 2018.
Former positions include Associate Director-Regulatory Affairs at Amylin Pharmaceuticals, Inc. from 1989 to 1997, Principal at Hybritech, Inc. from 1981 to 1989, Vice President-Regulatory Affairs at Syndax Pharmaceuticals, Inc. from 2008 to 2018, Vice President-Regulatory Affairs at OncoSec Medical, Inc., Vice President-Regulatory Affairs at Ascenta Therapeutics, Inc., and Vice President-Regulatory Affairs at FeRx, Inc. from 1997 to 2004.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GOSSAMER BIO, INC. 0,05 % | 19.03.2026 | 259 333 ( 0,05 % ) | 42 790 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | - |
Alevium Pharmaceuticals, Inc. | Vorstandsvorsitzender | 01.06.2009 |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Provides neurological treatment services | Direktor/Vorstandsmitglied | 23.06.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
DSC Associates LLC | Gründer | 01.01.2018 |
| SYNDAX PHARMACEUTICALS, INC. | General Counsel | 01.01.2018 |
FeRx, Inc.
FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | General Counsel | 01.01.2004 |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | General Counsel | 01.01.1997 |
Hybritech, Inc.
Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Corporate Officer/Principal | 01.01.1989 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Hybritech, Inc.
Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Commercial Services |
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
OncoSec Medical, Inc.
OncoSec Medical, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel immunotherapeutic products for immuno-oncology treatment | Health Technology |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines for cancer | Health Technology |
FeRx, Inc.
FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | Health Technology |
Alevium Pharmaceuticals, Inc. | |
DSC Associates LLC | |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Provides neurological treatment services | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen